Form 4: Neurocrine Biosciences CEO Kyle Gano Executes Stock Option and Sells Shares Under 10b5-1 Plan
SEC Form 4 Filing
Neurocrine Biosciences CEO Kyle Gano exercised stock options and sold shares of common stock on January 31, 2025, under a pre-arranged 10b5-1 trading plan.
Summary
- On January 31, 2025, Kyle Gano, the CEO of Neurocrine Biosciences Inc., engaged in transactions involving the company's common stock.
- Gano exercised restricted stock units (RSUs), converting them into 2,927 shares of common stock at a price of $0.
- Simultaneously, Gano sold 1,541 shares of common stock at a weighted average price of $152.8731, with individual sales prices ranging from $151.94 to $153.59.
- These transactions were executed under a Rule 10b5-1 trading plan adopted on September 14, 2022.
- Following these transactions, Gano directly owns 136,778 shares of Neurocrine Biosciences Inc.
- Gano also owns 2,927 restricted stock units.
Sentiment
Score: 5
Explanation: The document is a routine SEC filing detailing stock transactions by an executive. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.
Industry Context
Executive stock transactions are a common occurrence in publicly traded companies, and are often scrutinized by investors for insights into management's perspective on the company's value and future prospects. The use of 10b5-1 trading plans allows insiders to sell shares over a predetermined period, mitigating concerns about trading on non-public information.
Comparison to Industry Standards
- Executive compensation packages in the biotechnology industry often include a mix of salary, stock options, and restricted stock units.
- The vesting schedules for RSUs, such as the one described in the document, are typical for incentivizing long-term performance.
- The use of 10b5-1 trading plans is a standard practice among executives to manage their personal finances while avoiding accusations of insider trading.
- Comparing Gano's stock ownership and trading activity to those of CEOs at comparable biotech companies (e.g., Vertex Pharmaceuticals, Amgen, Biogen) would provide a benchmark for assessing the magnitude of his holdings and transactions.
Stakeholder Impact
- Shareholders may interpret the stock sale as a signal, although the existence of a 10b5-1 plan mitigates concerns about insider information.
- The transactions have no direct impact on employees, customers, suppliers, or creditors.
Key Dates
| Date | Description |
|---|---|
| 2022-09-14 | Date the Reporting Person adopted a Rule 10b5-1 trading plan |
| 2022-01-31 | Date the Restricted Stock Unit was granted to the Reporting Person |
| 2023-01-31 | Date the Restricted Stock Unit vested as to 2,926 shares |
| 2024-01-31 | Date the Restricted Stock Unit vested as to 2,926 shares |
| 2025-01-31 | Date of transaction (exercise of stock options and sale of shares); Date the Restricted Stock Unit vested as to 2,927 shares |
| 2026-01-31 | Date the Restricted Stock Unit will vest as to 2,927 shares |
| 2025-02-04 | Date of Form 4 filing |
Keywords
Neurocrine Biosciences, NBIX, Kyle Gano, Stock Sale, Form 4, Restricted Stock Units, 10b5-1 Trading Plan, Executive Compensation, Insider Trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.